Rickettsia helvetica
Rickettsia helvetica, previously known as the Swiss agent, is a bacterium found in "Dermacentor reticulatus" and other ticks, which has been implicated as a suspected but unconfirmed human pathogen. First recognized in 1979 in "Ixodes ricinus" ticks in Switzerland (hence the designation "helvetica") as a new member of the spotted fever group of "Rickettsia", the "R. helvetica" bacterium was eventually isolated in 1993. Although "R. helvetica" was initially thought to be harmless in humans and many animal species, some individual case reports suggest that it may be capable of causing a nonspecific fever in humans. In 1997, a  man living in eastern France seroconverted to "Rickettsia" 4 weeks after onset of an unexplained febrile illness. In 2010, a case report indicated that tick-borne "R. helvetica" can also cause meningitis in humans. Molecular evidence suggests that in Croatia, as many as 10% of "D. reticulatus" ticks are infected with "R. helvetica". In addition to this, "R. slovaca" is found in another 2%, and 1% are infected with both species. Signs and symptoms. Erythema migrans or rash was observed at all combinations of seroreactivity, with symptoms including fever, muscle pain, headache, and respiratory problems. The spots (erythema migrans) are  described as red spots, much lesser in size than those seen in Lyme disease, but sometimes no spots occur at all. Epidemiology. In 80 healthy Swedish blood donors, about 1% were seroreactive for "Rickettsia" spp., interpreted as past infection. In a prospective study of Swedish recruits who trained in the coastal areas, 8.9% showed seroconversion Treatment. As with other rickettsioses, the treatment of choice is doxycycline